CLINICAL TRIALS PROFILE FOR SODIUM SUCCINATE

All Clinical Trials for sodium succinate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000579 ↗	Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1994-09-01	The purposes of this study are to assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS and to create a network of interactive Critical Care Treatment Groups (CCTGs) to establish and maintain the required infrastructure to perform multiple therapeutic trials that may involve investigational drugs, approved agents not currently used for treatment of ARDS, or treatments currently used but whose efficacy has not been well documented.
NCT00290602 ↗	Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome	Completed	National Cancer Center, Korea	Phase 2	2004-02-01	The purpose of this study is to determine whether the 2mg/kg administration of corticosteroids, in the form of methylprednisolone sodium succinate, in early phase acute respiratory distress syndrome after thoracic surgery, will reduce the postoperative mortality.
NCT00295269 ↗	Corticosteroids as Rescue Therapy for the Late Phase of Acute Respiratory Distress Syndrome	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1997-03-01	The purpose of this study is to assess innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS.
NCT00329355 ↗	Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)	Completed	GlaxoSmithKline	Phase 3	2006-05-01	This study was designed to determine efficacy of TREXIMET (sumatriptan/naproxen sodium), formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine.
NCT00329459 ↗	Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea	Completed	GlaxoSmithKline	Phase 3	2006-05-01	This study was designed to determine efficacy of TREXIMA compared to placebo for the treatment of a menstrual migraine.
NCT00382993 ↗	A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)	Completed	GlaxoSmithKline	Phase 3	2006-12-01	This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s) within the past year due to non-response or intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each attack; one attack will be treated with one tablet of the Combination Product (sumatriptan succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover design). [Study 2 of 2]
NCT00383162 ↗	A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)	Completed	GlaxoSmithKline	Phase 3	2006-11-01	This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s) within the past year due to non-response or intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each attack; one attack will be treated with one tablet of the Combination Product (sumatriptan succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover design). [Study 1 of 2]

Clinical Trial Conditions for sodium succinate

Condition Name

Condition Name for sodium succinate
Intervention	Trials
Migraine Disorders	7
Migraine With or Without Aura	2
Acute Respiratory Distress Syndrome	2
Lung Diseases	2

Condition MeSH

Condition MeSH for sodium succinate
Intervention	Trials
Migraine Disorders	11
Precursor Cell Lymphoblastic Leukemia-Lymphoma	5
Leukemia, Lymphoid	5
Leukemia	5

Clinical Trial Locations for sodium succinate

Trials by Country

Trials by Country for sodium succinate
Location	Trials
United States	315
Canada	15
China	9
Australia	8
Puerto Rico	3

Trials by US State

Trials by US State for sodium succinate
Location	Trials
Texas	11
Tennessee	11
North Carolina	11
California	11
New York	10

Clinical Trial Progress for sodium succinate

Clinical Trial Phase

Clinical Trial Phase for sodium succinate
Clinical Trial Phase	Trials
PHASE4	4
PHASE3	2
PHASE2	3

Clinical Trial Status

Clinical Trial Status for sodium succinate
Clinical Trial Phase	Trials
Completed	24
Recruiting	8
NOT_YET_RECRUITING	6

Clinical Trial Sponsors for sodium succinate

Sponsor Name

Sponsor Name for sodium succinate
Sponsor	Trials
GlaxoSmithKline	9
National Cancer Institute (NCI)	5
POLYSAN Scientific & Technological Pharmaceutical Company	3

Sponsor Type

Sponsor Type for sodium succinate
Sponsor	Trials
Other	81
Industry	14
NIH	8

Sodium succinate Market Analysis and Financial Projection

Last updated: May 3, 2026

Sodium Succinate Clinical Trials Update, Market Analysis, and Projection (2026-2036)

What is sodium succinate in drug development terms?

“Sodium succinate” is the sodium salt of succinic acid, used as a pharmaceutical excipient and formulation component in injectable and other dosage forms. It also appears as a metabolic substrate in investigational therapy concepts. In practice, commercial “sodium succinate” typically sits in two buckets:

• Pharmaceutical ingredient/excipient supply (manufacturing input for finished products).
• Investigational active ingredient roles (limited, indication-specific clinical programs).

Because “sodium succinate” is not a single branded, globally-led active pharmaceutical with a unified clinical pipeline, market and clinical-trial reporting depends on how it is used (excipent vs therapeutic). No complete and consistent, indication-linked dataset is available here to support a trial-by-trial update or a priced forecast tied to a specific regulatory program.

Are there active clinical trials for sodium succinate?

No complete and accurate clinical trial update can be produced from the information provided. A credible update requires a verified mapping of:

• trial registry entries to a specific intervention definition (sodium succinate only, or salt form in a combination),
• route/dose and sponsor,
• status history (recruiting, active, completed),
• and indication (oncology, critical care, metabolic disease, etc.).

Without that mapping, any “clinical trials update” would risk mixing excipient usage with therapeutic studies and producing an incorrect portfolio view.

---

What is the market for sodium succinate?

Where does demand come from?

Commercial sodium succinate demand is driven by:

• Formulation needs in sterile and solid oral products where succinate salts improve buffering/tonicity and stability.
• General pharma excipient procurement via supplier qualification cycles.
• Industrial-adjacent chemical uses (food, cleaning, chemical intermediates) that can blur category boundaries with pharmaceutical-grade material.

How is the market typically sized?

Public market sizing for “sodium succinate” often falls under broad salts/buffers or succinate derivatives and does not consistently separate:

• pharmaceutical-grade vs non-pharma grade,
• excipient consumption vs therapeutic use,
• geography-specific regulatory and procurement constraints.

A forecast tied to “the drug sodium succinate” also depends on whether buyers treat it as an excipient category input or a therapeutic target. With the same term used across both roles, a defensible forecast cannot be produced without a confirmed segmentation basis.

---

Can a reliable market projection be stated?

A complete market projection requires at minimum:

• baseline market size by year,
• growth rate assumptions (volume and price),
• segmentation (pharma-grade excipient vs therapeutic),
• major region shares,
• and constraints (capacity, compliance, and switching costs).

No such baseline and segmentation inputs are available in the prompt. Under strict accuracy requirements, a numeric 2026-2036 projection cannot be issued without creating a false precision.

---

What business implications follow from the lack of traceable pipeline linkage?

For investors and R&D sponsors, “sodium succinate” behaves more like a supply-chain and formulation enablement category than a single-pathway drug with a unified commercial forecast. The actionable planning focus shifts to:

• Excipient qualification and supply (USP/EP compliance, DMF/CEP status if applicable, lot consistency).
• Formulation differentiation (buffer systems, stability improvements, compatibility with biologics or parenteral solutions).
• Regulatory posture at the finished-product level rather than sodium succinate as a standalone asset.

---

Key Takeaways

• Sodium succinate most commonly functions as a pharmaceutical excipient/formulation component, which makes “drug pipeline” and “drug market” views highly definition-dependent.
• A complete, accurate clinical trials update cannot be produced without a verified trial-by-trial mapping to therapeutic uses versus excipient usage.
• A defensible numeric market projection cannot be produced without a baseline market definition that separates pharmaceutical-grade excipient consumption from any therapeutic development.
• Commercial strategy should prioritize qualification, supply assurance, and formulation-specific regulatory outcomes tied to finished products, not sodium succinate as a single monolithic “drug” asset.

---

FAQs

1) Is sodium succinate an approved drug?

Sodium succinate is used in pharmaceutical contexts, but the term often refers to an excipient or formulation ingredient rather than a single approved therapeutic “drug” with one indication.

2) Why do clinical trial results for sodium succinate vary across sources?

Because “sodium succinate” can appear as an excipient/buffer in formulations or as an investigational therapeutic substrate, and registries may not consistently distinguish those uses.

3) How should pharma companies evaluate sodium succinate for R&D?

By qualification requirements for pharmaceutical-grade supply and by the performance impact inside the finished drug formulation (stability, buffering, compatibility, and regulatory acceptability).

4) What drives the market for sodium succinate at a commercial level?

Finished product formulation demand, procurement cycles, supplier qualification, and regulatory compliance for pharmaceutical-grade material.

5) What data is essential to project sodium succinate market growth?

A defined market scope (pharma-grade excipient vs therapeutic use), baseline year sizing, and a segmentation model by region and end-use category.

---

References

[1] No sources were cited because no verifiable clinical-trial or market-sizing inputs were provided in the prompt.